109 Days
المصدر:
الصحة والعلوم الشرق الأوسط
المصدر: الصحة والعلوم الشرق الأوسط
109 Daysالصحة والعلوم الشرق الأوسط
المصدر: الصحة والعلوم الشرق الأوسط
109 Daysجاهز للتشغيل
جاهز للتشغيل
An international clinical study has revealed that a new injection called "Amivantamab" showed promising results in reducing or eliminating tumors in patients with head and neck cancer who did not respond to traditional treatments. The study was conducted on 102 patients across 11 countries and resulted in tumor size reduction in 43 of them, with 15 patients completely clearing their tumors. Developed by Johnson & Johnson, this medication works by inhibiting growth receptors and helping the immune system attack the tumor. It is administered subcutaneously rather than intravenously. Currently, additional studies are underway to evaluate its effectiveness in other types of cancers such as lung, colon, and stomach cancers.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading